




U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
INFORMATION DISCLOSURE STATEMENT		Docket Number: 11245/48601	
Application Number 09/635,974	Filing Date August. 9, 2000	Examiner Tungaturthi, Parithosh K.	Art Unit 1643
Invention Title TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS		Inventors Thomas Teufel	

Address to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date: November 13, 2006

Signature: 

Lawrence P. Casson (Reg. No. 46,606)

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. Copies of information listed on the modified PTO Form 1449 are enclosed.
3. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.117(p) (submission of an information disclosure statement under § 1.97(c)) fee of **\$180.00**, and any additional fees that may be required in connection with this Information Disclosure Statement, to the deposit account of **Kenyon & Kenyon LLP**, deposit account number **11-0600**. A duplicate copy of this communication is enclosed for charging purposes.

Dated: November 13, 2006

By: 

Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON LLP

One Broadway

New York, N.Y. 10004

(212) 425-7200 (telephone)

(212) 425-5288 (facsimile)

Customer No. 26646


02 FC:1806

180.00 DA

11/17/2006 CHUUYEN 00000044 110600

09635974

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO - 1449 FORM	ATTY. DOCKET NO. 11245/48601	SERIAL NO. 09/635,974
	APPLICANT Thomas Teufel	
	FILING DATE August 9, 2000	GROUP 1643



U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCL ASS	FILING DATE*

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.	
	Cunningham, D., et al., ABSTRAT "Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer", The New England Journal of Medicine 351:337-45., July 22, 2004	
	Lenz, H., et al., ABSTRACT "Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines", Journal of Clinical Oncology, Vol.24, No.30, page 4914-4921 October 20, 2006	
	Trivin, F, et al., Letter to the Editor "Complete Sustained Regression of Extensive Psoriasis with Cetuximab Combination Chemotherapy", Acta Oncologica Vol.43, No.6, page 592-593, 2004	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	